(Q82332974)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20032971%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

title

CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20032971%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

1 reference

1 reference

B Stuhlmüller

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20032971%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

T Häupl

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20032971%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

M M Hernandez

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20032971%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

A Grützkau

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20032971%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

R-J Kuban

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20032971%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

N Tandon

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20032971%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

J W Voss

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20032971%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

J Salfeld

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20032971%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

R W Kinne

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20032971%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

G R Burmester

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20032971%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

publication date

23 December 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20032971%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

15 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20032971%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

volume

87

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20032971%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20032971%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

311-321

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20032971%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/clpt.2009.244

15 January 2020

exact match

0 references

cites work

An update on the cytokine network in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

Identification of known and novel genes in activated monocytes from patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

Adalimumab (Humira®) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade®) or etanercept (Enbrel®): results from the STURE registry at Karolinska University Hospital

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

Patients, their doctors, nonsteroidal anti-inflammatory drugs and the perception of risk

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

Molecular discrimination of responders and nonresponders to anti-TNF alpha therapy in rheumatoid arthritis by etanercept

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

Diffuse large B-cell lymphoma in a patient with rheumatoid arthritis treated with infliximab and methotrexate

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

Adverse dermatological reactions in rheumatoid arthritis patients treated with etanercept, an anti-TNFalpha drug

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

Anti-cytokine therapeutics and infections

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

Overexpression of synoviolin in peripheral blood and synoviocytes from rheumatoid arthritis patients and continued elevation in nonresponders to infliximab treatment

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

Identification of gene expression signatures in autoimmune disease without the influence of familial resemblance.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

Genes implicated in multiple sclerosis pathogenesis from consilience of genotyping and expression profiles in relapse and remission

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

Microarray analyses of peripheral blood cells identifies unique gene expression signature in psoriatic arthritis.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

Reactivation of rheumatoid arthritis after pregnancy: increased phagocyte and recurring lymphocyte gene activity

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

CD14+,CD16+ blood monocytes and joint inflammation in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

Monoclonal anti‐TNFα Antibody as a Probe of Pathogenesis and Therapy of Rheumatoid Disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

Monocyte and macrophage heterogeneity

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

Adhesion molecule expression on peripheral blood mononuclear cells in rheumatoid arthritis: positive correlation between the proportion of L-selectin and disease activity

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

Blood-derived inflammatory dendritic cells in lymph nodes stimulate acute T helper type 1 immune responses

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

Modulation of adhesion molecule profiles on alveolar macrophages and blood leukocytes

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

Ligation of CD31/PECAM-1 modulates the function of lymphocytes, monocytes and neutrophils.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

Disparate gene expression of chemotactic cytokines by human mononuclear phagocytes

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

Ligation of CD11b and CD11c beta(2) integrins by antibodies or soluble CD23 induces macrophage inflammatory protein 1alpha (MIP-1alpha) and MIP-1beta production in primary human monocytes through a pathway dependent on nuclear factor-kappaB.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

TNF-alpha neutralization in cytokine-driven diseases: a mathematical model to account for therapeutic success in rheumatoid arthritis but therapeutic failure in systemic inflammatory response syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

RNA sensors: novel regulators of gene expression

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

Points of control in inflammation

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

SiPaGene: A new repository for instant online retrieval, sharing and meta-analyses of GeneChip expression data

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

Genesis: cluster analysis of microarray data

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

A literature network of human genes for high-throughput analysis of gene expression

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

Diagnostic tests. 1: Sensitivity and specificity

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

Diagnostic tests 2: Predictive values

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

Diagnostic tests 3: receiver operating characteristic plots

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021

Clinical biostatistics. XXXIV. The other side of 'statistical significance': alpha, beta, delta, and the calculation of sample size

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.244

7 January 2021